Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Premkumar Reddy

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Stem Cells (Dayton, Ohio)|August 9, 2014
Myb permits multilineage airway epithelial cell differentiationJie-Hong Pan, Tracy L Adair-Kirk, Anand C Patel, et al.
Molecular Cancer|June 7, 2021
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeChi Yan, Nabil Saleh, Jinming Yang, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Cancer Research|February 14, 2016
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple MyelomaDeepak Perumal, Pei-Yu Kuo, Violetta V Leshchenko, et al.
Journal of Medicinal Chemistry|June 12, 2013
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agentsM V Ramana Reddy, Muralidhar R Mallireddigari, Venkat R Pallela, et al.
The Journal of Biological Chemistry|August 27, 2010
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndromeZhi-Xing Yao, Wilma Jogunoori, Sanaa Choufani, et al.
Hepatology (Baltimore, Md.)|April 27, 2011
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancerHye Jung Baek, Michael J Pishvaian, Yi Tang, et al.
Cell Reports. Medicine|July 8, 2025
Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancerShalini Nath, Sally Claridge, Genesis Lara Granados, et al.
Nature Communications|August 4, 2021
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant diseaseKatsutoshi Sato, Amol A Padgaonkar, Stacey J Baker, et al.
Journal of Medicinal Chemistry|January 15, 2014
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)M V Ramana Reddy, Balireddy Akula, Stephen C Cosenza, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Stem Cells (Dayton, Ohio)|August 9, 2014
Myb permits multilineage airway epithelial cell differentiationJie-Hong Pan, Tracy L Adair-Kirk, Anand C Patel, et al.
Molecular Cancer|June 7, 2021
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeChi Yan, Nabil Saleh, Jinming Yang, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Cancer Research|February 14, 2016
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple MyelomaDeepak Perumal, Pei-Yu Kuo, Violetta V Leshchenko, et al.
Journal of Medicinal Chemistry|June 12, 2013
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agentsM V Ramana Reddy, Muralidhar R Mallireddigari, Venkat R Pallela, et al.
The Journal of Biological Chemistry|August 27, 2010
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndromeZhi-Xing Yao, Wilma Jogunoori, Sanaa Choufani, et al.
Hepatology (Baltimore, Md.)|April 27, 2011
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancerHye Jung Baek, Michael J Pishvaian, Yi Tang, et al.
Cell Reports. Medicine|July 8, 2025
Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancerShalini Nath, Sally Claridge, Genesis Lara Granados, et al.
Nature Communications|August 4, 2021
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant diseaseKatsutoshi Sato, Amol A Padgaonkar, Stacey J Baker, et al.
Journal of Medicinal Chemistry|January 15, 2014
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)M V Ramana Reddy, Balireddy Akula, Stephen C Cosenza, et al.
Pageof 10